Peter J O'Dwyer

Inhibition of G1/S transition potentiates oxaliplatin-induced cell death in colon cancer cell lines.

P. O'dwyer, I. Vasilevskaya, Tatiana V Rakitina, 2007, Biochemical pharmacology.

A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis.

David Smith, Rebecca Sutphen, John J Rossi, 2009, Cancer research.

Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.

Weijing Sun, Daniel G Haller, Mark Rosen, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.

Gary Middleton, Takayuki Yoshino, Chloe E Atreya, 2018, Cancer discovery.

Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance.

Karin Reed, M. Murphy, P. O'dwyer, 2002, Biochemical pharmacology.

Gene expression patterns in ovarian carcinomas.

Trevor Hastie, Robert Tibshirani, David Botstein, 2003, Molecular biology of the cell.

NF-κB Activation by the Chemopreventive Dithiolethione Oltipraz Is Exerted through Stimulation of MEKK3 Signaling*

P. O'dwyer, Peter J O'Dwyer, Chu Won Nho, 2004, Journal of Biological Chemistry.

Guidelines for the use and interpretation of assays formonitoring autophagy (3rd edition)

Sangeeta Khare, Xin Qi, Ying Wang, 2016 .

Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias.

Dejan Juric, D. Juric, B. Sikic, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of sorafenib in advanced thyroid cancer.

Andrea B Troxel, Keith T Flaherty, K. Flaherty, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.